Markets

The Fundamental Case for and Against Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 1.57B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ICPT, the company currently has 62.03 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 615.75 million in total assets, balanced by 446.04 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Intercept Pharmaceuticals, Inc. (ICPT) saw -59.52 million in free cash flow last quarter, representing a quarterly net change in cash of -4.92 million. Perhaps most importantly where cash movements are concerned, the company saw about -55.31 million in net operating cash flow.



Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 30.89 million in total revenues. That represents a quarterly year/year change in revenues of 4.60 in sequential terms, the ICPT saw sales decline by 0.47.

But what about the bottom line? After all, that’s what really matters in the end. Intercept Pharmaceuticals, Inc. (ICPT) is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.35 million, yielding a gross basic income of 29.54 million. For shareholders, given the total diluted outstanding shares of 25.03 million, this means overall earnings per share of -3.46. Note, this compares with a consensus analyst forecast of -3.55 in earnings per share for its next fiscal quarterly report.




Is Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -12.04 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Intercept Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

Checking Out the Fundamental Data for BGC Partners... BGC Partners, Inc. (NASDAQ:BGCP) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants tryin...
Drilling Down Into the Books for Perion Network Lt... It is interesting to note that Perion Network Ltd. (NASDAQ:PERI) is active and made a solid movement in the last trading day. Now trading with a marke...
Goldcorp Inc. (GG) Makes An Interesting Case Right... Goldcorp Inc. (NYSE:GG) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with a market value of 10....
C. Penney Company, Inc. (JCP): Does This Move Make... C. Penney Company, Inc. (NYSE:JCP) is in the highlights and many would want to know whether now might be a good time for it to present much upside...
Dissecting the Numbers for Western Digital Corpora... Western Digital Corporation (NASDAQ:WDC) and NetApp, Inc. (NASDAQ:NTAP) are the two most active stocks in the Data Storage Devices industry based on t...